Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug ...

The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

In a report released on March 9, Matthew Henderson from J.P. Morgan maintained a Sell rating on Otsuka (OSUKF – Research Report), with a price ...

Otsuka America Pharmaceutical is continuing its work to provide support to and advocate for family caregivers. | Otsuka ...

Vera stock dropped after Otsuka announced plans for accelerated approval of sibeprenlimab. Learn why VERA stock is a Hold.

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Buy rating on Otsuka Holdings Co (OTSKF – Research Report), with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Otsuka licensed rights to Lupkynis in various ex-US markets including the EU, Japan and the UK in 2020, with Aurinia retaining rights to the drug in the US and its home market of Canada.

Shares of Vera Therapeutics (NASDAQ:VERA) lost ~20% on Friday to reach a new 52-week low, in a move attributed to a potential market launch of a rival kidney disease therapy from Otsuka Holdings ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...